OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 1, pp. e52-e61
Open Access | Times Cited: 340
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 1, pp. e52-e61
Open Access | Times Cited: 340
Showing 51-75 of 340 citing articles:
Doan C. Nguyen, Pedro A. Lamothe, Matthew C. Woodruff, et al.
Immunological Reviews (2022) Vol. 309, Iss. 1, pp. 40-63
Open Access | Times Cited: 41
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study
Ana Atti, Ferdinando Insalata, Edward J Carr, et al.
Journal of Infection (2022) Vol. 85, Iss. 5, pp. 545-556
Open Access | Times Cited: 39
Ana Atti, Ferdinando Insalata, Edward J Carr, et al.
Journal of Infection (2022) Vol. 85, Iss. 5, pp. 545-556
Open Access | Times Cited: 39
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study
Kathryn S. Hensley, Marlou J. Jongkees, Daryl Geers, et al.
PLoS Medicine (2022) Vol. 19, Iss. 10, pp. e1003979-e1003979
Open Access | Times Cited: 39
Kathryn S. Hensley, Marlou J. Jongkees, Daryl Geers, et al.
PLoS Medicine (2022) Vol. 19, Iss. 10, pp. e1003979-e1003979
Open Access | Times Cited: 39
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1175-1185
Open Access | Times Cited: 33
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1175-1185
Open Access | Times Cited: 33
An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants
Timothy A. Bates, Hans C. Leier, Savannah K. McBride, et al.
JCI Insight (2023) Vol. 8, Iss. 5
Open Access | Times Cited: 31
Timothy A. Bates, Hans C. Leier, Savannah K. McBride, et al.
JCI Insight (2023) Vol. 8, Iss. 5
Open Access | Times Cited: 31
Monoclonal antibody levels and protection from COVID-19
Eva Stadler, Martin Burgess, Timothy E. Schlub, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 31
Eva Stadler, Martin Burgess, Timothy E. Schlub, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 31
mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
Vivek P. Chavda, Gargi Jogi, Srusti Dave, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 507-507
Open Access | Times Cited: 30
Vivek P. Chavda, Gargi Jogi, Srusti Dave, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 507-507
Open Access | Times Cited: 30
B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Dennis Lapuente, Thomas Winkler, Matthias Tenbusch
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 144-158
Open Access | Times Cited: 29
Dennis Lapuente, Thomas Winkler, Matthias Tenbusch
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 144-158
Open Access | Times Cited: 29
Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron
Yuchen Wei, Katherine Min Jia, Shi Zhao, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e2254777-e2254777
Open Access | Times Cited: 28
Yuchen Wei, Katherine Min Jia, Shi Zhao, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e2254777-e2254777
Open Access | Times Cited: 28
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
David Benkeser, Youyi Fong, Holly Janes, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 26
David Benkeser, Youyi Fong, Holly Janes, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 26
Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference
Marianne Graninger, Claudia Jani, Elisabeth Reuberger, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 25
Marianne Graninger, Claudia Jani, Elisabeth Reuberger, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 25
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
Delphine Kemlin, Nicolas Gemander, Stéphanie Depickère, et al.
American Journal of Transplantation (2023) Vol. 23, Iss. 5, pp. 649-658
Open Access | Times Cited: 24
Delphine Kemlin, Nicolas Gemander, Stéphanie Depickère, et al.
American Journal of Transplantation (2023) Vol. 23, Iss. 5, pp. 649-658
Open Access | Times Cited: 24
Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses
Chang Yi Wang, Wen‐Jiun Peng, Be-Sheng Kuo, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 4, pp. e1010870-e1010870
Open Access | Times Cited: 24
Chang Yi Wang, Wen‐Jiun Peng, Be-Sheng Kuo, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 4, pp. e1010870-e1010870
Open Access | Times Cited: 24
Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines
Paulina Kapłonek, Yixiang Deng, Jessica Shih-Lu Lee, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 5, pp. 101048-101048
Open Access | Times Cited: 21
Paulina Kapłonek, Yixiang Deng, Jessica Shih-Lu Lee, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 5, pp. 101048-101048
Open Access | Times Cited: 21
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Congrui Zhu, Shengmei Pang, Jiaqi Liu, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 403-423
Closed Access | Times Cited: 9
Congrui Zhu, Shengmei Pang, Jiaqi Liu, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 403-423
Closed Access | Times Cited: 9
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
Samuel M. S. Cheng, Chris Ka Pun Mok, John K.C. Li, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 7
Samuel M. S. Cheng, Chris Ka Pun Mok, John K.C. Li, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 7
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial
Nawal Al Kaabi, Yun Yang, Li Fang Du, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36
Nawal Al Kaabi, Yun Yang, Li Fang Du, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
Neeltje van Doremalen, Jonathan E. Schulz, Danielle R. Adney, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36
Neeltje van Doremalen, Jonathan E. Schulz, Danielle R. Adney, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36
Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
Chloé Dimeglio, Marion Migueres, Naémie Bouzid, et al.
Vaccines (2022) Vol. 10, Iss. 9, pp. 1548-1548
Open Access | Times Cited: 36
Chloé Dimeglio, Marion Migueres, Naémie Bouzid, et al.
Vaccines (2022) Vol. 10, Iss. 9, pp. 1548-1548
Open Access | Times Cited: 36
SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022
Samuel M. S. Cheng, Chris Ka Pun Mok, Karl CK Chan, et al.
Eurosurveillance (2022) Vol. 27, Iss. 18
Open Access | Times Cited: 34
Samuel M. S. Cheng, Chris Ka Pun Mok, Karl CK Chan, et al.
Eurosurveillance (2022) Vol. 27, Iss. 18
Open Access | Times Cited: 34
Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, et al.
Blood (2022) Vol. 139, Iss. 9, pp. 1409-1412
Open Access | Times Cited: 33
Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, et al.
Blood (2022) Vol. 139, Iss. 9, pp. 1409-1412
Open Access | Times Cited: 33
Third dose of SARS‐CoV‐2 vaccine: A systematic review of 30 published studies
Fausto Petrelli, Andrea Luciani, Karen Borgonovo, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 6, pp. 2837-2844
Open Access | Times Cited: 33
Fausto Petrelli, Andrea Luciani, Karen Borgonovo, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 6, pp. 2837-2844
Open Access | Times Cited: 33
Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273
Carla A. Pascuale, Augusto Varese, Diego Ojeda, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 8, pp. 100706-100706
Open Access | Times Cited: 31
Carla A. Pascuale, Augusto Varese, Diego Ojeda, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 8, pp. 100706-100706
Open Access | Times Cited: 31
A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
Klara Lenart, Fredrika Hellgren, Sebastian Ols, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 27, pp. 309-323
Open Access | Times Cited: 31
Klara Lenart, Fredrika Hellgren, Sebastian Ols, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 27, pp. 309-323
Open Access | Times Cited: 31
